Hospira's quality issues weigh on Q4 results, 2012 forecast

The good news for Hospira: Quarterly sales rose 2.2% to more than $1 billion. The not-so-good: The costs of fixing manufacturing problems pushed earnings into the red. The company's net loss amounted to $212.3 million, or $1.30 per diluted share, Reuters reports.

According to documents filed with the Securities and Exchange Commission, Hospira's ($HSP) efforts to fix quality issues at its Rocky Mount, NC, facility have resulted in drug shortages, reduced production volume and associated costs. The company took charges of $36.8 million for third-party oversight and consulting costs in 2011, plus the financial fallout from reduced production. The company also took inventory losses of $28.5 million at the Rocky Mount facility.

The FDA scrutiny has led to manufacturing "interruptions [that] have adversely impacted, and continue to adversely impact, Hospira's ability to manufacture and sell its products," the company said in its 10-K filing. Hospira is expecting the manufacturing overhaul to continue to affect earnings: Its forecast for 2012 includes charges of 50 cents to 62 cents per share to cover the cost of addressing product and quality-related matters, Reuters reports.

- see the SEC filing
- get more from Reuters

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.